Demographic data for patients at study outset.4 Among the patients from the original cohort who were alive at follow up (n = 108), data are only given for those who agreed to participate in the follow up element of the study (n = 99, 92%)
| Baseline variable | All patients | Patients alive at follow up | Patients dead at follow up |
|---|---|---|---|
| Unless otherwise indicated, data are presented as median (range). | |||
| UDCA, ursodeoxycholic acid; FIS, fatigue impact score; na, not applicable | |||
| Age (y) | 65 (21–88) | 62 (21–88) | 77 (53–86) |
| Bilirubin (μmol/l) | 8 (3–131) | 8 (3–131) | 10 (4–69) |
| Albumin (g/l) | 42 (28–51) | 42 (28–51) | 40 (35.5–45) |
| Prothrombin time (s) | 13 (11–24) | 13 (11–24) | 13 (12–18) |
| UDCA therapy (n (%)) | 39 (31) | 28 (28) | 11 (39) |
| Definite disease (n (%)) | 81 (64) | 62 (63) | 19 (68) |
| Probable disease (n (%)) | 46 (36) | 37 (37) | 9 (32) |
| Histologically confirmed advanced disease (n (%)) | 14 (11) | 9 (9) | 5 (18) |
| Pruritus present at enrolment (n (%)) | 84 (62) | 64 (59) | 20 (71) |
| FIS at enrolment | 40.5 (0–138) | 35.5 (0–136) | 54.5 (2–138) |
| FIS at follow up | na | 37.5 (0–142) | na |
| Female (n (%)) | 116 (91) | 90 (91) | 26 (93) |